Search

Your search keyword '"Brouwer, Johannes T."' showing total 157 results
Start Over Author "Brouwer, Johannes T."
157 results on '"Brouwer, Johannes T."'

1. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy

Author

van Gerven, N.M., Beuers, U., van Erpecum, K.J., den Ouden, J.W., Bhalla, A., Vrolijk, J.M., Koek, G.H., Guichelaar, M.M.J., van Meyel, J.J.M., Baak, L.C., Klemt-Kropp, M., Verhagen, M.A.M.T., Kuijvenhoven, J.Ph., de Jonge, H.M., Stoelinga, Anna E.C., Biewenga, Maaike, Drenth, Joost P.H., Verhelst, Xavier, van der Meer, Adriaan J.P., de Boer, Ynto S., Bouma, Gerd, de Vries, Elsemieke S., Verdonk, Robert C., van der Berg, Aad P., Brouwer, Johannes T., Vanwolleghem, Thomas, Lammers, Wim, Beuers, Ulrich, Sarasqueta, Arantza Farina, Verheij, Joanne, Roskams, Tania, Crobach, Stijn, Tushuizen, Maarten E., and van Hoek, Bart

Published
2024
Full Text
View/download PDF

2. Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial

Author

Goltstein, Lia C.M.J., Grooteman, Karina V., Bernts, Lucas H.P., Scheffer, Robert C.H., Laheij, Robert J.F., Gilissen, Lennard P.L., Schrauwen, Ruud W.M., Talstra, Nynke C., Zuur, Abraham T., Braat, Henri, Hadithi, Muhammed, Brouwer, Johannes T., Nagengast, Wouter B., Oort, Frank A., Tenthof van Noorden, Jacco, Kievit, Wietske, van Geenen, Erwin J.M., and Drenth, Joost P.H.

Published
2024
Full Text
View/download PDF

3. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

van Gerven, N., van Erpecum, K., Ouden, J den, Brouwer, J., Vrolijk, J., Gevers, T.J., Drenth, J., Guichelaar, M., Bouma, G., Schreuder, T.C.M.A., van der Wouden, E.J., Baak, L.C., Stadhouders, P., Klemt-Kropp, M., Verhagen, M., Bhalla, A., Kuijvenhoven, J., Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Invernizzi, P., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Lopez, S. Ines, de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Vergani, D., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Colapietro, Francesca, Maisonneuve, Patrick, Lytvyak, Ellina, Beuers, Ulrich, Verdonk, Robert C., van der Meer, Adriaan J., van Hoek, Bart, Kuiken, Sjoerd D., Brouwer, Johannes T., Muratori, Paolo, Aghemo, Alessio, Carella, Francesco, van den Berg, Ad P., Zachou, Kalliopi, Dalekos, George N., Di Zeo-Sánchez, Daniel E., Robles, Mercedes, Andrade, Raul J., Montano-Loza, Aldo J., van den Brand, Floris F., Slooter, Charlotte D., Macedo, Guilherme, Liberal, Rodrigo, de Boer, Ynto S., and Lleo, Ana

Published
2024
Full Text
View/download PDF

4. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study)

Author

MS MDL 1, Cancer, Infection & Immunity, Farag, Mina S., van Campenhout, Margo J.H., Sonneveld, M. J., Fung, Scott, van Erpecum, Karel J., Wong, David K., Verhey, Elke, de Man, Robert, De Knegt, Robert J., Brouwer, Johannes T., Baak, Hubertus C., Feld, Jordan J., Liem, Kin Seng, Boonstra, André, Hansen, Bettina E., Janssen, Harry L.A., MS MDL 1, Cancer, Infection & Immunity, Farag, Mina S., van Campenhout, Margo J.H., Sonneveld, M. J., Fung, Scott, van Erpecum, Karel J., Wong, David K., Verhey, Elke, de Man, Robert, De Knegt, Robert J., Brouwer, Johannes T., Baak, Hubertus C., Feld, Jordan J., Liem, Kin Seng, Boonstra, André, Hansen, Bettina E., and Janssen, Harry L.A.

Published
2024

5. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy

Author

Stoelinga, Anna E.C., Biewenga, Maaike, Drenth, Joost P.H., Verhelst, Xavier, van der Meer, Adriaan J.P., de Boer, Ynto S., Bouma, Gerd, de Vries, Elsemieke S., Verdonk, Robert C., van der Berg, Aad P., Brouwer, Johannes T., Vanwolleghem, Thomas, Lammers, Wim, Beuers, U., Sarasqueta, Arantza Farina, Verheij, Joanne, Roskams, Tania, Crobach, Stijn, Tushuizen, Maarten E., van Hoek, Bart, Stoelinga, Anna E.C., Biewenga, Maaike, Drenth, Joost P.H., Verhelst, Xavier, van der Meer, Adriaan J.P., de Boer, Ynto S., Bouma, Gerd, de Vries, Elsemieke S., Verdonk, Robert C., van der Berg, Aad P., Brouwer, Johannes T., Vanwolleghem, Thomas, Lammers, Wim, Beuers, U., Sarasqueta, Arantza Farina, Verheij, Joanne, Roskams, Tania, Crobach, Stijn, Tushuizen, Maarten E., and van Hoek, Bart

Abstract

Background & Aims: Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) can co-exist in AIH-PBC, requiring combined treatment with immunosuppression and ursodeoxycholic acid (UDCA). The Paris criteria are commonly used to identify these patients; however, the optimal diagnostic criteria are unknown. We aimed to evaluate the use and clinical relevance of both Paris and Zhang criteria. Methods: Eighty-three patients with a clinical suspicion of AIH-PBC who were treated with combination therapy were included. Histology was re-evaluated. Characteristics and long-term outcomes were retrospectively compared to patients with AIH and PBC. Results: Seventeen (24%) patients treated with combination therapy fulfilled the Paris criteria. Fifty-two patients (70%) fulfilled the Zhang criteria. Patients who met Paris and Zhang criteria more often had inflammation and fibrosis on histology compared to patients only meeting the Zhang criteria. Ten-year liver transplant (LT)-free survival was 87.3% (95% CI 78.9–95.7%) in patients with AIH-PBC. This did not differ in patients in or outside the Paris or Zhang criteria (p = 0.46 and p = 0.40, respectively) or from AIH (p = 0.086). LT-free survival was significantly lower in patients with PBC and severe hepatic inflammation – not receiving immunosuppression – compared to those with AIH-PBC (65%; 95% CI 52.2–77.8% vs. 87%; 95% CI 83.2–90.8%; hazard ratio 0.52; p = 0.043). Conclusions: In this study, patients with AIH-PBC outside Paris or Zhang criteria were frequently labeled as having AIH-PBC and were successfully treated with combination therapy with similar outcomes. LT-free survival was worse in patients with PBC and hepatic inflammation than in those treated as having AIH-PBC. More patients may benefit from combination therapy. Impact and implications: This study demonstrated that patients with AIH-PBC variant syndro

Published
2024

6. Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B

Author

Farag, Mina S., primary, van Campenhout, Margo J. H., additional, Sonneveld, M. J., additional, Fung, Scott, additional, van Erpecum, Karel J., additional, Wong, David K., additional, Verhey, Elke, additional, de Man, Robert, additional, De Knegt, Robert J., additional, Brouwer, Johannes T., additional, Baak, Hubertus C., additional, Feld, Jordan J., additional, Liem, Kin Seng, additional, Boonstra, André, additional, Hansen, Bettina E., additional, and Janssen, Harry L. A., additional

Published
2024
Full Text
View/download PDF

7. Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial

Author

Goltstein, Lia C.M.J., primary, Grooteman, Karina V., additional, Bernts, Lucas H.P., additional, Scheffer, Robert C.H., additional, Laheij, Robert J.F., additional, Gilissen, Lennard P.L., additional, Schrauwen, Ruud W.M., additional, Talstra, Nynke C., additional, Zuur, Abraham T., additional, Braat, Henri, additional, Hadithi, Muhammed, additional, Brouwer, Johannes T., additional, Nagengast, Wouter B., additional, Oort, Frank A., additional, Tenthof van Noorden, Jacco, additional, Kievit, Wietske, additional, van Geenen, Erwin J.M., additional, and Drenth, Joost P.H., additional

Published
2023
Full Text
View/download PDF

8. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

Colapietro, Francesca, primary, Maisonneuve, Patrick, additional, Lytvyak, Ellina, additional, Beuers, Ulrich, additional, Verdonk, Robert C., additional, van der Meer, Adriaan J., additional, van Hoek, Bart, additional, Kuiken, Sjoerd D., additional, Brouwer, Johannes T., additional, Muratori, Paolo, additional, Aghemo, Alessio, additional, Carella, Francesco, additional, van den Berg, Ad P., additional, Zachou, Kalliopi, additional, Dalekos, George N., additional, Di Zeo-Sánchez, Daniel E., additional, Robles, Mercedes, additional, Andrade, Raul J., additional, Montano-Loza, Aldo J., additional, van den Brand, Floris F., additional, Slooter, Charlotte D., additional, Macedo, Guilherme, additional, Liberal, Rodrigo, additional, de Boer, Ynto S., additional, Lleo, Ana, additional, van Gerven, N., additional, van Erpecum, K., additional, Ouden, J den, additional, Brouwer, J., additional, Vrolijk, J., additional, Gevers, T.J., additional, Drenth, J., additional, Guichelaar, M., additional, Bouma, G., additional, Schreuder, T.C.M.A., additional, van der Wouden, E.J., additional, Baak, L.C., additional, Stadhouders, P., additional, Klemt-Kropp, M., additional, Verhagen, M., additional, Bhalla, A., additional, Kuijvenhoven, J., additional, Almasio, P., additional, Alvarez, F., additional, Andrade, R., additional, Arikan, C., additional, Assis, D., additional, Bardou-Jacquet, E., additional, Biewenga, M., additional, Cancado, E., additional, Cazzagon, N., additional, Chazouillères, O., additional, Colloredo, G., additional, Cuarterolo, M., additional, Dalekos, G., additional, Debray, D., additional, Robles-Díaz, M., additional, Dyson, J., additional, Efe, C., additional, Engel, B., additional, Ferri, S., additional, Fontana, R., additional, Gatselis, N., additional, Gerussi, A., additional, Halilbasic, E., additional, Halliday, N., additional, Heneghan, M., additional, Hirschfield, G., additional, van Hoek, B., additional, Hørby Jørgensen, M., additional, Indolfini, G., additional, Iorio, R., additional, Invernizzi, P., additional, Jeong, S., additional, Jones, D., additional, Kelly, D., additional, Kerkar, N., additional, Lacaille, F., additional, Lammert, C., additional, Leggett, B., additional, Lenzi, M., additional, Levy, C., additional, Liberal, R., additional, Lleo, A., additional, Lohse, A., additional, Lopez, S. Ines, additional, de Martin, E., additional, McLin, V., additional, Mieli-Vergani, G., additional, Milkiewicz, P., additional, Mohan, N., additional, Muratori, L., additional, Nebbia, G., additional, van Nieuwkerk, C., additional, Oo, Y., additional, Ortega, A., additional, Páres, A., additional, Pop, T., additional, Pratt, D., additional, Purnak, T., additional, Ranucci, G., additional, Rushbrook, S., additional, Schramm, C., additional, Stättermayer, A., additional, Swain, M., additional, Tanaka, A., additional, Taubert, R., additional, Terrabuio, D., additional, Terziroli, B., additional, Trauner, M., additional, Valentino, P., additional, van den Brand, F., additional, Vergani, D., additional, Villamil, A., additional, Wahlin, S., additional, Ytting, H., additional, Zachou, K., additional, and Zeniya, M., additional

Published
2023
Full Text
View/download PDF

9. Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis

Author

Fischer, Susan E., de Vries, Elsemieke S., Tushuizen, Maarten E., de Boer, Ynto S., van der Meer, Adriaan J.P., de Man, Robert A., Brouwer, Johannes T., Kuyvenhoven, Johan P., Klemt-Kropp, Michael, Gevers, Tom J.G., Tjwa, Eric T.T.L., Kuiper, Edith M.M., Verhagen, Marc A.M.T., Friederich, Philip W., van Hoek, Bart, Fischer, Susan E., de Vries, Elsemieke S., Tushuizen, Maarten E., de Boer, Ynto S., van der Meer, Adriaan J.P., de Man, Robert A., Brouwer, Johannes T., Kuyvenhoven, Johan P., Klemt-Kropp, Michael, Gevers, Tom J.G., Tjwa, Eric T.T.L., Kuiper, Edith M.M., Verhagen, Marc A.M.T., Friederich, Philip W., and van Hoek, Bart

Abstract

Background and Aims: While some articles describe outcome of pregnancy in autoimmune hepatitis (AIH), there are less data evaluating influence of AIH control on maternal and perinatal outcomes. This study analysed outcomes of pregnancy and related possible risk factors in AIH. Method: A retrospective multicentre cohort study on pregnancy in AIH was performed in 11 hospitals in the Netherlands. Maternal and neonatal outcomes were collected from records and completed by interview. Risk factors—including incomplete response, relapse and cirrhosis—for adverse outcomes were identified using logistic regression analysis. Results: Ninety-seven pregnancies in 50 women resulted in 70 deliveries (72%) with a live birth rate of 98.5%. AIH relapse occurred in 6% during pregnancy, and in 27% of post-partum episodes. Absence of complete biochemical response at conception was identified as risk factor for the occurrence of gestational and post-partum relapses. Relapse of AIH in the year before conception was a risk factor for the occurrence of both gestational relapses and post-partum relapses. No complete biochemical response increased the risk for hypertensive disorders during pregnancy and intrahepatic cholestasis of pregnancy (ICP). Cirrhosis was found to be a risk factor for miscarriages, but not for other outcomes. Conclusion: Pregnancy in AIH is related to an increased incidence of maternal and fetal/neonatal complications; in most cases, outcome is good. Incomplete biochemical response at conception or relapse in the year before conception are risk factors for gestational and post-partum relapses, for hypertensive disorders and for ICP. Cirrhosis was a risk factor for miscarriages.

Published
2023

10. Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis

Author

Fischer, Susan E., primary, de Vries, Elsemieke S., additional, Tushuizen, Maarten E., additional, de Boer, Ynto S., additional, van der Meer, Adriaan J. P., additional, de Man, Robert A., additional, Brouwer, Johannes T., additional, Kuyvenhoven, Johan P., additional, Klemt‐Kropp, Michael, additional, Gevers, Tom J. G., additional, Tjwa, Eric T. T. L., additional, Kuiper, Edith M. M., additional, Verhagen, Marc A. M. T., additional, Friederich, Philip W., additional, and van Hoek, Bart, additional

Published
2023
Full Text
View/download PDF

11. Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1

Author

de Boer, Ynto S., van Gerven, Nicole M.F., Zwiers, Antonie, Verwer, Bart J., van Hoek, Bart, van Erpecum, Karel J., Beuers, Ulrich, van Buuren, Henk R., Drenth, Joost P.H., den Ouden, Jannie W., Verdonk, Robert C., Koek, Ger H., Brouwer, Johannes T., Guichelaar, Maureen M.J., Vrolijk, Jan M., Kraal, Georg, Mulder, Chris J.J., van Nieuwkerk, Carin M.J., Fischer, Janett, Berg, Thomas, Stickel, Felix, Sarrazin, Christoph, Schramm, Christoph, Lohse, Ansgar W., Weiler-Normann, Christina, Lerch, Markus M., Nauck, Matthias, Völzke, Henry, Homuth, Georg, Bloemena, Elisabeth, Verspaget, Hein W., Kumar, Vinod, Zhernakova, Alexandra, Wijmenga, Cisca, Franke, Lude, and Bouma, Gerd

Published
2014
Full Text
View/download PDF

12. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission

Author

van Gerven, Nicole M.F., Verwer, Bart J., Witte, Birgit I., van Hoek, Bart, Coenraad, Minneke J., van Erpecum, Karel J., Beuers, Ulrich, van Buuren, Henk R., de Man, Rob A., Drenth, Joost P.H., den Ouden, Jannie W., Verdonk, Robert C., Koek, Ger H., Brouwer, Johannes T., Guichelaar, Maureen M.J., Mulder, Chris J.J., van Nieuwkerk, Karin M.J., and Bouma, Gerd

Published
2013
Full Text
View/download PDF

13. 867d: OCTREOTIDE SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENTS COMPARED TO STANDARD CARE IN PATIENTS WITH ANGIODYSPLASIA-RELATED ANEMIA: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Author

Goltstein, Liat, primary, Bernts, Lucas H., additional, Grooteman, Karina V., additional, Scheffer, Bob, additional, Laheij, Robert, additional, Gilissen, Lennard, additional, Schrauwen, Ruud W., additional, Talstra, Nynke C., additional, Zuur, Abraham T., additional, Braat, Henri, additional, Hadithi, Muhammed, additional, Brouwer, Johannes T., additional, Nagengast, Wouter B., additional, Oort, Frank A., additional, Noorden, Jacco Tenthof van, additional, Kievit, Wietske, additional, Geenen, Erwin-Jan M. Van, additional, and Drenth, Joost, additional

Published
2022
Full Text
View/download PDF

14. Cytotoxic T Lymphocyte Antigen–4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis

Author

van Gerven, Nicole M. F., de Boer, Ynto S., Zwiers, Antonie, van Hoek, Bart, van Erpecum, Karel J., Beuers, Ulrich, van Buuren, Henk R., Drenth, Joost P. H., den Ouden, Jannie W., Verdonk, Robert C., Koek, Ger H., Brouwer, Johannes T., Guichelaar, Maureen M. J., Vrolijk, Jan M., Kraal, G., Mulder, Chris J. J., van Nieuwkerk, Carin. M. J., and Bouma, Gerd

Published
2013
Full Text
View/download PDF

25. Hepatitis C virus genotypes: epidemiological and clinical associations

Author

Kleter, Bernhard, Brouwer, Johannes T., Nevens, Frederik, van Doorn, Leen-Jan, Elewaut, Andre, Versieck, Jacques, Michielsen, Peter P., Hautekeete, March L., Chamuleau, Rob A. F. M., Brénard, Réginald, Bourgeois, Nadine, Adler, Michael, Quint, Wim G. V., Bronkhorst, Carolien M., Heijtink, Rudolf A., Hop, Wim J. C., Fevery, Johan, and Schalm, Solko W.

Published
1998

32. Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

Author

Delwaide Jean, Michielsen Peter, Nevens Frederik, Adler Michael, Brouwer Johannes T, Veldt Bart J, Hansen Bettina E, and Schalm Solko W

Subjects
Hepatitis C, Treatment, Randomised controlled trial, Interferon, Ribavirin, Non-responders, Monotherapy, Placebo, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Evidence based medicine depends on unbiased selection of completed randomized controlled trials. For completeness it is important to publish all trials. This report describes the first large randomised controlled trial where combination therapy was compared to placebo therapy and to ribavirin monotherapy, which has not been published untill now. Methods One hundred and twenty one patients with chronic hepatitis C and elevated transaminases who did not respond to previous treatment with standard interferon monotherapy, were included from 16 centers in Belgium, the Netherlands and Luxembourg between 1992 and 1996. Patient poor-response characteristics were: genotype 1 (69%), HCV RNA above 2 × 106 copies/ml (55%) and cirrhosis (38%). Patients were randomized to 6 months combination therapy with interferon alpha-2b (3 MU tiw) and ribavirin (1000–1200 mg / day), 6 months ribavirin monotherapy (1000–1200 mg / day) or 6 months ribavirin placebo. The study was double blinded for the ribavirin / placebo component. One patient did not fit the entry criteria, and 3 did not start. All 117 patients who received at least one dose of treatment were included in the intention to treat analysis. Results At the end of treatment, HCV RNA was undetectable in 35% of patients on combination therapy and in none of the patients treated with ribavirin monotherapy or placebo. The sustained virological response rate at 6 months after therapy was 15% for patients treated with interferon and ribavirin. During the 6 months treatment period 13% of patients on interferon ribavirin combination therapy, 13% of patients on ribavirin monotherapy and 11% of patients on placebo withdrew due to side effects or noncompliance. At 24 weeks of treatment the mean Hb level was 85% of the baseline value, which means a mean decrease from 9.1 mmol/l to 7.8 mmol/l. The Hb levels at the end of treatment were not significantly different from patients treated with ribavirin monotherapy (p = 0.76). End of treatment WBC was significantly lower in patients treated with combination therapy, compared to ribavirin (p < 0.01) as well as for patients treated with ribavirin monotherapy compared to placebo (p < 0.01). Discussion This belated report on the only placebo controlled study of interferon ribavirin combination therapy in non responders to standard doses of interferon monotherapy documents the effectiveness, be it limited, of this approach as well as the dynamics of the effects on blood counts.

Published
2003
Full Text
View/download PDF

34. Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study

Author

Levi-Drummer Rachel S, Brouwer Johannes T, Neumann Avidan U, Bekkering Frank C, and Schalm Solko W

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background High dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied. Methods A new model that allowed longitudinal changes in the parameters of viral dynamics was used in a group of genotype-1 patients (N = 15) with dose reduction from 10 to 3 million units of interferon daily in combination with ribavirin, in comparison to a control group (N = 9) with no dose reduction. Results Dose reduction gave rise to a complex viral kinetic pattern, which could be only explained by a decrease in interferon effectiveness in blocking virion production. The benefit of the rapid initial viral decline following the high induction dose is lost after dose reduction. In addition, in some patients also the second phase viral decline slope, which is highly predictive of success of treatment, was impaired by the dose reduction resulting in smaller percentage of viral clearance in the dose reduction group. Conclusions These findings, while explaining the failure of many induction schedules, suggest that for genotype-1 patients induction therapy should be continued till HCVRNA negativity in serum in order to increase the sustained response rate for chronic hepatitis C.

Published
2001
Full Text
View/download PDF

36. Mycophenolate mofetil: role in autoimmune hepatitis and overlap syndromes

Author

Baven-Pronk, Martine A.M.C., Coenraad, Minneke J., Van Buuren, Henk, De Man, Robert A, Van Erpecum, Karel J, Lamers, Mieke M.H., Drenth, Joost, Van Den Berg, Aad A.P., Beuers, Ulrich, Den Ouden, Jannie, Koek, Ger H., Van Nieuwkerk, Carin M.J., Bouma, Gerd, Brouwer, Johannes T., Van Hoek, Bart, Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Gastroenterology, University Medical Center [Utrecht], Radboud University Medical Center [Nijmegen], University Medical Center Groningen [Groningen] (UMCG), Department of Gastroenterology & Hepatology, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), HAGA Hospital, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Free University Medical Center [Amsterdam], and Reinier de Graaf Gasthuis

Subjects
Medicine
Abstract

International audience; Background and Aims: Treatment failure occurs in 20% of autoimmune hepatitis patients on prednisolone and azathioprine (AZA). There is no established second line treatment. This retrospective observational study was conducted to assess the efficacy of mycophenolate mofetil as second line treatment after AZA-intolerance or AZA-nonresponse in autoimmune hepatitis and overlap syndromes. Methods: Consecutive patients from the Dutch Autoimmune Hepatitis Group cohort, consisting of 661 patients , with autoimmune hepatitis or overlap syndromes, AZA-intolerance or AZA-nonresponse, and past or present use of mycophenolate mofetil were included. Primary endpoint of mycophenolate mofetil treatment was biochemical remission. Secondary endpoints were biochemical response (without remission), treatment failure and prevention of disease progression. Results: Forty-five patients treated with mycophenolate mofetil were included. In autoimmune hepatitis remission or response was achieved in 13% and 27% in the AZA-nonresponse group compared to 67% and 0% in the AZA-intolerance group (P = 0.008). In overlap-syndromes remission or response was reached in 57% and 14% in the AZA-nonresponse group and 63% and 25% of the AZA-intolerance group (NS). 33% had side-effects and 13% discontinued mycophenolate mofetil. Overall 38% had treatment failure; this was 60% in the autoimmune hepatitis AZA-nonresponse group. Decompensated liver cirrhosis, liver transplantations and death were only seen in the autoimmune hepatitis AZA-nonresponse group (P < 0.001). Conclusion: Mycophenolate mofetil induced response or remission in a majority of patients with autoimmune hepatitis and azathioprine-intolerance and with overlap syndromes, irrespective of intolerance or nonresponse for azathioprine. In autoimmune hepatitis with azathioprine nonresponse mycophenolate mofetil is less often efective.

Published
2011
Full Text
View/download PDF

38. Mo1254 Colonoscopy Performed by Nurse Endoscopists is Associated With High Patient Satisfaction

Author

Van Putten, Paul G., primary, Massl, Renate, additional, Steyerberg, Ewout W., additional, Van Tilburg, Antonie J.P., additional, Lai, Jonathan, additional, De Ridder, Rogier J., additional, Brouwer, Johannes T., additional, Verburg, Robert, additional, Alderliesten, Joyce, additional, Schoon, Erik J., additional, Van Leerdam, Monique, additional, and Kuipers, Ernst J., additional

Published
2012
Full Text
View/download PDF

39. Su1297 Quality Assessment of Colonoscopies Performed by Nurse and Physician Endoscopists Reveals High Safety and Good Quality in Nurse Endoscopists

Author

Massl, Renate, primary, Van Putten, Paul G., additional, Steyerberg, Ewout W., additional, Van Tilburg, Antonie J.P., additional, Lai, Jonathan, additional, De Ridder, Rogier J., additional, Brouwer, Johannes T., additional, Verburg, Robert, additional, Alderliesten, Joyce, additional, Schoon, Erik J., additional, Kuipers, Ernst J., additional, and Van Leerdam, Monique, additional

Published
2012
Full Text
View/download PDF

40. Maintenance Treatment is Necessary Even When Auto Immune Hepatitis is in Remission

Author

van Gerven, Nicole M., primary, Verwer, Bart J., additional, Mulder, Chris J., additional, Guichelaar, Maureen, additional, van Hoek, Bart, additional, Pronk, Martine, additional, Coenraad, Minneke J., additional, van Buuren, Henk R., additional, De Man, Robert A., additional, Van Erpecum, Karel J., additional, Drenth, Joost P., additional, Beuers, Ulrich, additional, den Ouden, Jannie, additional, Koek, Ger H., additional, Brouwer, Johannes T., additional, van Nieuwkerk, Karin, additional, and Bouma, Gerd, additional

Published
2011
Full Text
View/download PDF

41. Epidemiology of Autoimmune Hepatitis in the Netherlands: A Nationwide Study

Author

van Gerven, Nicole M., primary, Verwer, Bart J., additional, van Hoek, Bart, additional, Brouwer, Johannes T., additional, Visscher, Arjan P., additional, Pronk, Martine, additional, Coenraad, Minneke J., additional, van Buuren, Henk R., additional, De Man, Robert A., additional, Van Erpecum, Karel J., additional, Drenth, Joost P., additional, Beuers, Ulrich, additional, de Zwart, Brenda, additional, den Ouden, Jannie, additional, Koek, Ger H., additional, van Nieuwkerk, Karin, additional, and Bouma, Gerd, additional

Published
2011
Full Text
View/download PDF

42. Evaluation of a Quality Assurance Program for Endoscopy Services in the Netherlands

Author

Sint Nicolaas, Jerome, primary, de Jonge, Vincent, additional, ter Borg, Frank, additional, Brouwer, Johannes T., additional, Cahen, Djuna L., additional, Kubben, Frank J., additional, Lesterhuis, Wilco, additional, Moolenaar, Willem, additional, Ouwendijk, Rob J., additional, Stolk, Mark, additional, Tang, Thjon J., additional, van Tilburg, Antonie J.P., additional, Valori, Roland M., additional, van Leerdam, Monique, additional, and Kuipers, Ernst J., additional

Published
2011
Full Text
View/download PDF

43. Tu1446 Quality of Colonoscopy From a Patient's Perspective Using the Global Rating Scale

Author

Nicolaas, Jerome Sint, primary, De Jonge, Vincent, additional, Van Baalen, Onno, additional, Borg, Frank Ter, additional, Brouwer, Johannes T., additional, Cahen, Djuna L., additional, Colpaert, E.E., additional, Lesterhuis, Wilco, additional, Moolenaar, Willem, additional, Ouwendijk, Rob J., additional, Stolk, Mark, additional, Tang, Thjon J., additional, Van Tilburg, Antonie J.P., additional, Kuipers, Ernst J., additional, and Van Leerdam, Monique, additional

Published
2011
Full Text
View/download PDF

44. Tu1474 Quality of Colonoscopy Reporting and Performance

Author

De Jonge, Vincent, primary, Nicolaas, Jerome Sint, additional, Van Baalen, Onno, additional, Borg, Frank Ter, additional, Brouwer, Johannes T., additional, Cahen, Djuna L., additional, Hadithi, Muhammed, additional, Lesterhuis, Wilco, additional, Moolenaar, Willem, additional, Ouwendijk, Rob J., additional, Stolk, Mark, additional, Tang, Thjon J., additional, Van Tilburg, Antonie J.P., additional, Kuipers, Ernst J., additional, and Van Leerdam, Monique, additional

Published
2011
Full Text
View/download PDF

45. Tu1496 The Occurrence of Adverse Events in a 30-Day Period After Colonoscopy

Author

De Jonge, Vincent, primary, Nicolaas, Jerome Sint, additional, Van Baalen, Onno, additional, Borg, Frank Ter, additional, Brouwer, Johannes T., additional, Cahen, Djuna L., additional, Ganesh, Sjam, additional, Lesterhuis, Wilco, additional, Moolenaar, Willem, additional, Ouwendijk, Rob J., additional, Stolk, Mark, additional, Tang, Thjon J., additional, Van Tilburg, Antonie J.P., additional, Kuipers, Ernst J., additional, and Van Leerdam, Monique, additional

Published
2011
Full Text
View/download PDF

46. Mo1374 Differences in Adenoma Detection Rate Between Endoscopy Departments

Author

De Jonge, Vincent, primary, Sint Nicolaas, Jerome, additional, Van Baalen, Onno, additional, Ter Borg, Frank, additional, Brouwer, Johannes T., additional, Cahen, Djuna L., additional, Kubben, Frank J., additional, Lesterhuis, Wilco, additional, Moolenaar, Willem, additional, Ouwendijk, Rob J., additional, Stolk, Mark, additional, Tang, Thjon J., additional, Van Tilburg, Antonie J.P., additional, Van Leerdam, Monique, additional, and Kuipers, Ernst J., additional

Published
2011
Full Text
View/download PDF

48. ?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?-2b in chronic hepatitis C non-responders

Author

Bergmann, Jilling F., primary, Vrolijk, Jan M., additional, van der Schaar, Peter, additional, Vroom, Brigitte, additional, van Hoek, Bart, additional, van der Sluys Veer, Annet, additional, de Vries, Richard A., additional, Verhey, Elke, additional, Hansen, Bettina E., additional, Brouwer, Johannes T., additional, Janssen, Harry L. A., additional, Schalm, Solko W., additional, and de Knegt, Robert J., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results